Get the Stockscreener App
8.31
1.59%
0.13
Intellia Therapeutics Inc stock is traded at $8.31, with a volume of 1.94M.
It is up +1.59% in the last 24 hours and down -4.81% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$8.18
Open:
$8.12
24h Volume:
1.94M
Relative Volume:
0.60
Market Cap:
$819.86M
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-1.5164
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
+14.94%
1M Performance:
-4.81%
6M Performance:
-47.90%
1Y Performance:
-58.49%
1-Day Range:
$7.91
$8.33
1-Week Range:
$7.15
$8.90
52-Week Range:
$5.90
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
8.31 | 819.86M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - Benzinga
Cathie Wood’s ARK offloads Meta, boosts Intellia stock - Investing.com Australia
Cathie Wood’s ARK offloads Meta, boosts Intellia stock By Investing.com - Investing.com South Africa
Is Intellia Therapeutics Inc (NASDAQ:NTLA) A Better Buy Than Others After A -62.53% Fall In This Year? - Marketing Sentinel
Insider Sale Alert: Intellia Therapeutics Inc [NTLA] – Is it Time to sell? - knoxdaily.com
Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation - PR Newswire
Wolfe Research Upgrades Intellia Therapeutics (NTLA) - Nasdaq
Intellia Therapeutics shares up after Wolfe upgrade - MSN
Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research - marketscreener.com
Intellia Therapeutics (NTLA) Surges After Upgrade from Wolfe Research - GuruFocus
NTLA’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Intellia Therapeutics (NTLA) Advances Nex-z in Phase III Trial for ATTRv-PN - GuruFocus
Intellia Therapeutics (NTLA) Eyes Growth with Gene Editing Advances - GuruFocus
Intellia Therapeutics (NTLA) Receives Upgrade to Outperform from Wolfe Research | NTLA Stock News - GuruFocus
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
New Horizons in Biomedical CRISPR Gene Editing Market Exploring - openPR.com
Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21 - marketscreener.com
How the (NTLA) price action is used to our Advantage - news.stocktradersdaily.com
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The ... - Bluefield Daily Telegraph
Intellia Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
Final Deadline Today for the Intellia Therapeutics, Inc. Securit - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Final Deadline Today for the Intellia Therapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsNTLA - The Malaysian Reserve
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA)April 14, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Business Wire
FINAL REMINDER NTLA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Intellia Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit - markets.businessinsider.com
NTLA Investors are Reminded of the Final Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Malaysian Reserve
NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc. - TipRanks
Intellia Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsNTLA - PR Newswire
NTLA Deadline: NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
FINAL NTLA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Intellia Therapeutics, Inc. Investors to Join the Class Action Lawsuit - markets.businessinsider.com
NTLA Investors Have the Opportunity to Lead the Intellia - GlobeNewswire
NTLA Investors Have the Opportunity to Lead the Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Morningstar
NTLA DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. - Bluefield Daily Telegraph
NTLA DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
התראת מועד אחרון לתביעה נגד NTLA: רוזן, למשקיעים מוכר, מעודד את משקיעי Intellia Therapeutics, Inc עם הפסדים העולים על 100 אלף דולר, להבטיח ייעוץ לפני המועד האחרון החשוב של 14 באפריל בתביעה ייצוגית בניירות ערך – NTLA - GlobeNewswire Inc.
Intellia Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
NTLA Deadline: Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $50K to Contact the Firm for Information About Their Rights - Eagle-Tribune
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - PR Newswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Intellia Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com
The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNTLA - PR Newswire
NTLA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, - GlobeNewswire
NTLA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. - Bluefield Daily Telegraph
Lost Money on Intellia Therapeutics, Inc. (NTLA)? Join - GlobeNewswire
Lost Money on Intellia Therapeutics, Inc. (NTLA)? Join Class Action Suit Seeking Recovery – ... - Bluefield Daily Telegraph
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Morningstar
Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple - Insider Monkey
Vanguard Group Inc. Has $118.82 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
| BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '25 |
Sale |
12.18 |
9,557 |
116,404 |
87,666 |
| Hicks Derek | EVP, Chief Business Officer |
Jan 03 '25 |
Sale |
12.18 |
6,502 |
79,194 |
59,878 |
| LEONARD JOHN M | President and CEO |
Jan 03 '25 |
Sale |
12.18 |
26,807 |
326,509 |
941,115 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '25 |
Sale |
12.18 |
8,966 |
109,206 |
77,388 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 03 '25 |
Sale |
12.18 |
7,422 |
90,400 |
64,048 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 02 '25 |
Sale |
12.03 |
556 |
6,689 |
71,470 |
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):